ideasIdea
Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre
Cervical cancer cannot be cured by external radiotherapy alone; it needs internal radiation, which many hospitals lack. A cheaper internal-radiation unit using a long-lived source could be placed in every regional centre.
Brachytherapy is essential for curative cervical cancer treatment, yet many LMIC radiotherapy centres have none or have units whose iridium-192 sources cannot be replaced every three months for cost and logistics reasons. Cobalt-60 HDR sources last about five years and are dosimetrically equivalent for cervix. A programme to fund cobalt HDR units, standardise applicators and image-guided planning, and train teams would close a specific and well-understood cure gap.
Hypothesis
Regional centres receiving a cobalt HDR unit and training will increase the proportion of locally advanced cervical cancer patients completing brachytherapy within the recommended overall treatment time from under 40% to above 80%.
Rationale
The technology is proven and the indication is common; the constraint is a solvable procurement and training problem with a defined cost.
What would test it
Before-and-after audit of brachytherapy completion, overall treatment time, and three-year local control in ten centres receiving units.
Maturity
early clinical
Who has to act
engineering
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
- Surgery and radiotherapy cure most, get least · Surgery and radiotherapy cure more people than drugs do, but attract a fraction of the research investment.